Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Indraccolo

Showing results (51-60 of 160) with videos related to

Pageof 16
Sort By:
Frontiers in Oncology|September 25, 2020
<i>In situ</i> Metabolic Profiling of Ovarian Cancer Tumor Xenografts: A Digital Pathology ApproachIlaria Piga, Martina Verza, Francesca Montenegro, et al.
Frontiers in Oncology|March 17, 2023
Metabolic classification of non-small cell lung cancer patient-derived xenografts by a digital pathology approach: A pilot studyFederica Ferrarini, Elisabetta Zulato, Massimo Moro, et al.
British Journal of Cancer|March 10, 2022
Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?Laura Bonanno, Alessandro Dal Maso, Alberto Pavan, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2006
Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironmentStefano Indraccolo, Laura Stievano, Sonia Minuzzo, et al.
The Journal of Gene Medicine|April 5, 2002
Encapsulated cells producing retroviral vectors for in vivo gene transferRobert M Saller, Stefano Indraccolo, Vincenzo Coppola, et al.
Frontiers in Oncology|February 1, 2021
Detection of Low-Frequency <i>KRAS</i> Mutations in cfDNA From <i>EGFR</i>-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase InhibitorsGiorgia Nardo, Jessica Carlet, Ludovica Marra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2010
Vandetanib improves anti-tumor effects of L19mTNFalpha in xenograft models of esophageal cancerMarika Crescenzi, Luca Persano, Giovanni Esposito, et al.
International Journal of Cancer|April 10, 2007
hTERT inhibits the Epstein-Barr virus lytic cycle and promotes the proliferation of primary B lymphocytes: implications for EBV-driven lymphomagenesisLiliana Terrin, Riccardo Dolcetti, Irene Corradini, et al.
Human Gene Therapy|June 28, 2003
Antiangiogenic therapy against experimental glioblastoma using genetically engineered cells producing interferon-alpha, angiostatin, or endostatinSophie De Boüard, Jean-Sébastien Guillamo, Christo Christov, et al.
Anticancer Research|December 29, 2010
Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinomaLaura Bonanno, Marco Schiavon, Giorgia Nardo, et al.
Pageof 16

Showing results (51-60 of 160) with videos related to

Sort By:
Pageof 16
Frontiers in Oncology|September 25, 2020
<i>In situ</i> Metabolic Profiling of Ovarian Cancer Tumor Xenografts: A Digital Pathology ApproachIlaria Piga, Martina Verza, Francesca Montenegro, et al.
Frontiers in Oncology|March 17, 2023
Metabolic classification of non-small cell lung cancer patient-derived xenografts by a digital pathology approach: A pilot studyFederica Ferrarini, Elisabetta Zulato, Massimo Moro, et al.
British Journal of Cancer|March 10, 2022
Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?Laura Bonanno, Alessandro Dal Maso, Alberto Pavan, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2006
Interruption of tumor dormancy by a transient angiogenic burst within the tumor microenvironmentStefano Indraccolo, Laura Stievano, Sonia Minuzzo, et al.
The Journal of Gene Medicine|April 5, 2002
Encapsulated cells producing retroviral vectors for in vivo gene transferRobert M Saller, Stefano Indraccolo, Vincenzo Coppola, et al.
Frontiers in Oncology|February 1, 2021
Detection of Low-Frequency <i>KRAS</i> Mutations in cfDNA From <i>EGFR</i>-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase InhibitorsGiorgia Nardo, Jessica Carlet, Ludovica Marra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2010
Vandetanib improves anti-tumor effects of L19mTNFalpha in xenograft models of esophageal cancerMarika Crescenzi, Luca Persano, Giovanni Esposito, et al.
International Journal of Cancer|April 10, 2007
hTERT inhibits the Epstein-Barr virus lytic cycle and promotes the proliferation of primary B lymphocytes: implications for EBV-driven lymphomagenesisLiliana Terrin, Riccardo Dolcetti, Irene Corradini, et al.
Human Gene Therapy|June 28, 2003
Antiangiogenic therapy against experimental glioblastoma using genetically engineered cells producing interferon-alpha, angiostatin, or endostatinSophie De Boüard, Jean-Sébastien Guillamo, Christo Christov, et al.
Anticancer Research|December 29, 2010
Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinomaLaura Bonanno, Marco Schiavon, Giorgia Nardo, et al.
Pageof 16